Highlights from the report:
Shares bounced from 10-WMA support, steadily progressing toward 52-week highs. While shares are extended from a conventional entry point, we recommend adding to existing positions.
New Zealand (
) is one of the best performing APAC markets, trading 1% off 52-week highs.
The stock displays significant technical strength with RS and A/D Ratings of 97 and A-, respectively. Its RS line is near all-time highs. The stock has been in an uptrend, finding support at its 50-DMA.
Growth is fueled by its infant formula (IF) products that are offered through its exclusive A2 Milk agreement in China and Australasia. Further growth opportunities lie in China’s New Hope and Bright Dairy IF, which are both expected to receive Chinese Food and Drug Administration approval this year. Coupled with capacity expansion, which reflects management’s medium-term confidence, consensus expects revenue and EPS to have a CAGR of 18% and 40%, respectively, from 2017 to 2020.